Baird Medical Showcases Advanced Ablation Technology at 2025 American Thyroid Association Annual Meeting
Baird Medical (NASDAQ: BDMD), a leader in Microwave Ablation (MWA) technology, showcased its innovations at the 2025 American Thyroid Association Annual Meeting. The company's exhibition featured live demonstrations of their MWA systems and attracted physicians from the U.S., Europe, and South America.
A highlight was the Expo Theater session featuring Dr. Emad Kandil from Tulane University, who presented data from over 200 MWA procedures. Notably, the presentation included evidence of MWA's effectiveness in 19 patients where previous Radiofrequency Ablation (RFA) treatments had failed. Dr. Kandil endorsed MWA as a safe and effective treatment for both benign and malignant thyroid nodules across adult and pediatric populations.
Baird Medical (NASDAQ: BDMD), leader nella tecnologia di Microwave Ablation (MWA), ha presentato le sue innovazioni al 2025 American Thyroid Association Annual Meeting. L'esibizione dell’azienda ha incluso dimostrazioni dal vivo dei sistemi MWA e ha richiamato medici da Stati Uniti, Europa e America Latina.
Uno dei momenti chiave è stata la sessione Expo Theater con il Dott. Emad Kandil della Tulane University, che ha illustrato dati provenienti da più di 200 procedure MWA. In particolare, la presentazione ha riportato evidenze sull’efficacia della MWA in 19 pazienti in cui i trattamenti di Radiofrequency Ablation (RFA) precedenti avevano fallito. Il Dott. Kandil ha sostenuto la MWA come trattamento sicuro ed efficace per noduli tiroidei benigni e maligne, sia negli adulti che nei bambini.
Baird Medical (NASDAQ: BDMD), líder en la tecnología de Microwave Ablation (MWA), presentó sus innovaciones en la Reunión Anual 2025 de la American Thyroid Association. La exhibición de la empresa incluyó demostraciones en vivo de sus sistemas MWA y atrajo a médicos de Estados Unidos, Europa y América del Sur.
Un punto destacado fue la sesión Expo Theater con el Dr. Emad Kandil de la Tulane University, quien presentó datos de más de 200 procedimientos MWA. Notablemente, la presentación incluyó evidencia de la efectividad de la MWA en 19 pacientes donde fracasaron tratamientos previos de Radiofrequency Ablation (RFA). El Dr. Kandil respaldó la MWA como un tratamiento seguro y eficaz para nódulos tiroideos benignos y malignos, tanto en adultos como en pediatría.
Baird Medical (NASDAQ: BDMD)는 Microwave Ablation(MWA) 기술의 선두주자로, 2025년 American Thyroid Association 연례 회의에서 혁신을 선보였습니다. 회사의 전시에는 MWA 시스템의 실시간 시연이 포함되었고 미국, 유럽, 남미의 의사들이 참여했습니다.
하이라이트는 Tulane University의 Dr. Emad Kandil이 진행한 Expo Theater 세션으로, 200건이 넘는 MWA 시술 데이터를 발표했습니다. 특히 발표는 이전의 RFA 치료가 실패한 19명 환자에서의 MWA 효과를 입증하는 내용을 담고 있습니다. Kandil 박사는 성인 및 소아를 대상으로 양성 및 악성 갑상선 결절에 대해 MWA를 안전하고 효과적인 치료로 지지했습니다.
Baird Medical (NASDAQ: BDMD), leader de la technologie d’ Microwave Ablation (MWA), a présenté ses innovations lors de la 2025 American Thyroid Association Annual Meeting. L’exposition de l’entreprise comprenait des démonstrations en direct de leurs systèmes MWA et a attiré des médecins des États-Unis, d’Europe et d’Amérique du Sud.
Un point fort a été la session Expo Theater avec le Dr Emad Kandil de l’Université Tulane, qui a présenté des données provenant de plus de 200 procédures MWA. Notamment, la présentation a inclus des preuves de l’efficacité de la MWA chez 19 patients pour lesquels les traitements RFA antérieurs avaient échoué. Le Dr Kandil a approuvé la MWA comme un traitement sûr et efficace pour les nodules thyroïdiens bénins et malins chez l’adulte et l’enfant.
Baird Medical (NASDAQ: BDMD), ein führendes Unternehmen in der Mikrowellenablation (MWA)-Technologie, stellte seine Innovationen auf der 2025 American Thyroid Association Annual Meeting vor. Der Unternehmensstand bot Live-Demonstrationen seiner MWA-Systeme und zog Ärzte aus den USA, Europa und Südamerika an.
Ein Höhepunkt war die Expo Theater-Sitzung mit Dr. Emad Kandil von der Tulane University, der Daten aus über 200 MWA-Verfahren präsentierte. Bemerkenswert war, dass die Präsentation Belege für die Wirksamkeit von MWA bei 19 Patienten zeigte, bei denen frühere Radiofrequency Ablation (RFA) fehlgeschlagen war. Dr. Kandil befürwortete MWA als sichere und wirksame Behandlung sowohl benigner als auch maligner Schilddrüsenknoten bei Erwachsenen und Kindern.
Baird Medical (NASDAQ: BDMD)، رائدة في تكنولوجيا الاستئصال الميكروي بالموجات (MWA)، عرضت ابتكاراتها في اجتماع الجمعية الأمريكية للغدة الدرقية 2025. تضمنت جناح الشركة عروضًا حية لأنظمة MWA وجذب أطباء من الولايات المتحدة وأوروبا وأمريكا الجنوبية.
كان من أبرز الأحداث جلسة Expo Theater مع الدكتور عماد Kandil من جامعة تولين، الذي قدم بيانات من أكثر من 200 إجراء MWA. ووجدت العرض التقديمي أدلة على فعالية MWA في 19 مريضًا فشلت لديهم علاجات RFA السابقة. وأكد الدكتور Kandil أن MWA إجراء آمن وفعال لعقد الغدة الدرقية الحميدة والخبيثة لدى البالغين والأطفال.
Baird Medical（纳斯达克股票代码：BDMD），在微波消融（MWA）技术领域居于领先地位，在2025年美国甲状腺协会年会上展示了其创新。公司的展览包括对其 MWA 系统的现场演示，吸引了来自美国、欧洲和南美的医生。
其中一个亮点是 Expo Theater 环节，由 Tulane University 的 Kandil 博士 主讲，展示了 超过 200 例 MWA 手术的数据。值得关注的是，此次演示包含了在 先前的射频消融（RFA）治疗失败的 19 例患者中 MWA 的疗效证据。Kandil 博士认为，MWA 对成人及儿童人群的良性与恶性甲状腺结节均是一种安全且有效的治疗方法。
- None.
- None.
The Company's exhibition booth served as a central hub for leading endocrinologists, surgeons, and researchers from the
A key highlight of the conference was Baird Medical's Expo Theater session, which featured a presentation by Dr. Emad Kandil, Professor and Ellis Hanna Chair in Surgery at Tulane University School of Medicine. Moderated by Dr. Salem Noureldine from the George Washington University Medical Center, the session provided a comprehensive clinical overview of MWA. Dr. Kandil presented compelling data from his experience with over 200 MWA procedures. Crucially, his presentation detailed a cohort of 19 patients for whom MWA proved effective after previous Radiofrequency Ablation (RFA) treatments had failed, underscoring MWA's potential as a vital treatment alternative.
Based on his extensive clinical evidence, Dr. Kandil concluded, "Microwave Ablation of thyroid nodules is a novel, safe, and effective method for treating appropriately selected benign and malignant thyroid nodules in both adult and pediatric populations. It can provide advantages compared to other thermal ablation techniques." The session prompted a dynamic Q&A, reflecting the growing clinical interest in the technology's applications.
Baird Medical's successful participation at the ATA meeting reinforces its commitment to collaborating with the global medical community to advance the standard of care for thyroid disease and improve patient outcomes worldwide.
About Baird Medical
Baird Medical is a forward-thinking medical device company specializing in minimally invasive diagnostics and treatment. It is dedicated to the research and development of surgical robotic systems and innovative minimally invasive surgical instruments. Our mission is to enhance patient outcomes through precision technology and advanced diagnostic solutions. The company will foster strategic collaborations with leading academic institutions. Our vision extends beyond surgical assistance, aiming to develop intelligent systems that proactively guide diagnostic decisions and preventive healthcare strategies. As an FDA 510(k)-certified medical device company, Baird Medical's solutions have been used in over 30 prestigious hospitals and clinics across
Forward-Looking Statements
This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical's future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as "may", "could", "should", "expect", "intend", "might", "will", "estimate", "anticipate", "believe", "budget", "forecast", "intend", "plan", "potential", "predict", "potential" or "continue", or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements.
Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in China or the
The foregoing list of factors is not exclusive. Additional information concerning certain of these and other risk factors is contained in ExcelFin's most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.
Contact:
Eric Huang, PR Liaison
Baird Medical Investment Holdings Ltd.
Phone: +1 (888) 508-6228
Email: ir@bairdmed.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/baird-medical-showcases-advanced-ablation-technology-at-2025-american-thyroid-association-annual-meeting-302569127.html
SOURCE BDMD
FAQ
When did Baird Medical (BDMD) present at the 2025 ATA Annual Meeting?
What clinical data did Dr. Kandil present about Baird Medical's MWA technology?
What are the advantages of Baird Medical's Microwave Ablation technology for thyroid treatment?
Who were the key speakers at Baird Medical's ATA presentation?
